The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely expl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology Jg. 8; S. 631
Hauptverfasser: Veluchamy, John P., Kok, Nina, van der Vliet, Hans J., Verheul, Henk M. W., de Gruijl, Tanja D., Spanholtz, Jan
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 31.05.2017
Schlagworte:
adoptive natural killer cell therapy
allogeneic natural killer cells
autologous natural killer cells
hematopoietic stem cell transplantation
Immunology
natural killer cell biotech companies
natural killer cell combinatorial studies
adoptive natural killer cell therapy
hematopoietic stem cell transplantation
natural killer cell combinatorial studies
allogeneic natural killer cells
natural killer cell biotech companies
autologous natural killer cells
ISSN:1664-3224, 1664-3224
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
AbstractList Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
Author de Gruijl, Tanja D.
Spanholtz, Jan
Verheul, Henk M. W.
Veluchamy, John P.
van der Vliet, Hans J.
Kok, Nina
AuthorAffiliation 2 Glycostem Therapeutics , Oss , Netherlands
1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam , Amsterdam , Netherlands
AuthorAffiliation_xml – name: 1 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam , Amsterdam , Netherlands
– name: 2 Glycostem Therapeutics , Oss , Netherlands
Author_xml – sequence: 1
  givenname: John P.
  surname: Veluchamy
  fullname: Veluchamy, John P.
– sequence: 2
  givenname: Nina
  surname: Kok
  fullname: Kok, Nina
– sequence: 3
  givenname: Hans J.
  surname: van der Vliet
  fullname: van der Vliet, Hans J.
– sequence: 4
  givenname: Henk M. W.
  surname: Verheul
  fullname: Verheul, Henk M. W.
– sequence: 5
  givenname: Tanja D.
  surname: de Gruijl
  fullname: de Gruijl, Tanja D.
– sequence: 6
  givenname: Jan
  surname: Spanholtz
  fullname: Spanholtz, Jan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28620386$$D View this record in MEDLINE/PubMed
BookMark eNp1UkFvFCEUJqbG1tq7J8PRy64wMMyMB5PNanVjo6apZ8LAY5eGgRVmNunF3y67W5vWRA5AeN_3vcd730t0EmIAhF5TMmes7d5ZNwzTvCK0mRMiGH2GzqgQfMaqip88up-ii5xvSVm8Y4zVL9Bp1YqKsFacod83G8DXLgOOFi-8j2sI4DT-psYpKY-_Ou8h4SV4n_EiY4V_eDXamAZcNrxUQZfwqlQS4riBpLZ37_E1aAgjXoUQd2p0MRReMPhyKpqAP8IOfNwOBZJfoedW-QwX9-c5-nn56Wb5ZXb1_fNqubia6bpqx5kS2qqm7m3XUQ2Gk54ywgX0QjAQwpIS1aQDQjvO26alpqMdFZoaa3gLhp2j1VHXRHUrt8kNKt3JqJw8PMS0liqNTnuQgtuaMwWaNpxTZnrRGE1ET7UFpsxe68NRazv1A5j9V0unnog-jQS3keu4kzWvCaFtEXh7L5DirwnyKAeXdemwChCnLEvppOlYGVKBvnmc6yHJ3wEWADkCdIo5J7APEErk3ibyYBO5t4k82KRQxD8U7cbDmEq1zv-f-Acj5MT-
CitedBy_id crossref_primary_10_3390_cells13131148
crossref_primary_10_3389_fonc_2019_00196
crossref_primary_10_1182_blood_2020009871
crossref_primary_10_3389_fimmu_2020_02028
crossref_primary_10_3389_fimmu_2022_904133
crossref_primary_10_3390_cells10092250
crossref_primary_10_1002_ajh_26529
crossref_primary_10_1158_0008_5472_CAN_18_3962
crossref_primary_10_1002_advs_201802045
crossref_primary_10_1016_j_xphs_2019_02_007
crossref_primary_10_1016_j_ijid_2019_01_039
crossref_primary_10_1053_j_seminhematol_2018_08_007
crossref_primary_10_1016_j_omto_2022_10_011
crossref_primary_10_3390_vaccines9090958
crossref_primary_10_1002_cac2_12394
crossref_primary_10_3389_fmolb_2021_754443
crossref_primary_10_1002_cyto_a_24941
crossref_primary_10_1016_j_bios_2022_114616
crossref_primary_10_3389_fimmu_2020_00873
crossref_primary_10_3389_fimmu_2023_1197053
crossref_primary_10_1155_2020_8459496
crossref_primary_10_1038_s41598_020_59082_4
crossref_primary_10_1016_j_bioadv_2022_213059
crossref_primary_10_3389_fimmu_2023_1101918
crossref_primary_10_1053_j_seminhematol_2023_02_002
crossref_primary_10_3390_cancers13225866
crossref_primary_10_3390_nu13092930
crossref_primary_10_3390_cancers12061591
crossref_primary_10_1016_j_jcyt_2020_02_001
crossref_primary_10_3389_fimmu_2022_953849
crossref_primary_10_1007_s00262_021_03117_w
crossref_primary_10_1038_s41417_021_00336_2
crossref_primary_10_3389_fimmu_2024_1460437
crossref_primary_10_1177_10732748211038735
crossref_primary_10_1002_advs_201800447
crossref_primary_10_3390_cancers13184722
crossref_primary_10_1007_s12272_019_01143_y
crossref_primary_10_1016_S2352_3026_25_00142_5
crossref_primary_10_1136_jitc_2021_003050
crossref_primary_10_3390_cancers13040711
crossref_primary_10_3389_fimmu_2021_780145
crossref_primary_10_1080_14712598_2019_1559293
crossref_primary_10_1038_s41571_020_0426_7
crossref_primary_10_3390_cancers13215446
crossref_primary_10_3389_fcell_2021_675310
crossref_primary_10_3390_vaccines8030447
crossref_primary_10_3389_fimmu_2018_00262
crossref_primary_10_1186_s13045_022_01382_5
crossref_primary_10_3389_fimmu_2020_618427
crossref_primary_10_3389_fimmu_2020_561553
crossref_primary_10_3390_biomedicines10030655
crossref_primary_10_3390_ijms26136290
crossref_primary_10_1186_s40425_019_0612_2
crossref_primary_10_3389_fimmu_2023_1175118
crossref_primary_10_1016_j_lfs_2023_121997
crossref_primary_10_3389_fimmu_2024_1420205
crossref_primary_10_3389_fimmu_2019_03026
crossref_primary_10_1039_C8BM01470A
crossref_primary_10_1007_s11060_019_03091_5
crossref_primary_10_3390_cells9040811
crossref_primary_10_4049_jimmunol_1801146
crossref_primary_10_1002_JLB_2MA0620_074R
crossref_primary_10_1007_s00262_023_03492_6
crossref_primary_10_1016_j_tips_2023_08_009
crossref_primary_10_3390_ph14030236
crossref_primary_10_1158_1078_0432_CCR_21_0164
crossref_primary_10_3390_cancers11101534
crossref_primary_10_3389_fimmu_2022_884648
crossref_primary_10_1002_jcp_26878
crossref_primary_10_1007_s10238_025_01559_5
crossref_primary_10_1002_jev2_12387
crossref_primary_10_3390_cells12030448
crossref_primary_10_1186_s40164_023_00431_0
crossref_primary_10_3389_fimmu_2021_640082
crossref_primary_10_1158_2326_6066_CIR_22_0391
crossref_primary_10_1186_s12935_021_02400_1
crossref_primary_10_1007_s00262_020_02532_9
crossref_primary_10_3389_fimmu_2019_02683
crossref_primary_10_1002_ajh_25983
crossref_primary_10_3389_fimmu_2021_765705
crossref_primary_10_1002_adbi_202000298
crossref_primary_10_1016_j_smim_2019_03_004
crossref_primary_10_3390_cancers14184439
crossref_primary_10_3389_fimmu_2019_00946
crossref_primary_10_1016_j_heliyon_2024_e35509
crossref_primary_10_1016_j_jtct_2022_12_025
crossref_primary_10_3389_fimmu_2021_633205
crossref_primary_10_1002_eji_201948375
crossref_primary_10_1155_2018_4054815
crossref_primary_10_1016_j_ymthe_2019_10_009
crossref_primary_10_3389_fimmu_2022_995645
crossref_primary_10_3748_wjg_v26_i33_4900
crossref_primary_10_1159_000540962
crossref_primary_10_3390_cancers12082131
crossref_primary_10_1002_sctm_19_0423
crossref_primary_10_2217_imt_2019_0040
crossref_primary_10_1097_BS9_0000000000000023
crossref_primary_10_1080_14712598_2020_1688298
crossref_primary_10_3390_cancers11060769
crossref_primary_10_1016_j_drudis_2022_103436
crossref_primary_10_1016_j_ymthe_2024_01_027
crossref_primary_10_29328_journal_jsctt_1001015
crossref_primary_10_31083_j_fbl2908284
crossref_primary_10_1016_j_jcyt_2021_03_006
crossref_primary_10_1038_s41467_020_19094_0
crossref_primary_10_1007_s11684_018_0653_9
crossref_primary_10_1016_j_devcel_2020_02_016
crossref_primary_10_1039_D1NH00179E
crossref_primary_10_3390_ijms20184490
crossref_primary_10_3390_ijms222111385
crossref_primary_10_1016_j_cellimm_2024_104898
crossref_primary_10_1016_j_exphem_2018_12_005
crossref_primary_10_3390_jcm8101702
crossref_primary_10_1007_s00262_022_03165_w
crossref_primary_10_1002_adhm_202101177
crossref_primary_10_1038_s41467_023_41625_8
crossref_primary_10_3390_cancers12071807
crossref_primary_10_1016_j_biopha_2023_115888
crossref_primary_10_1038_s41598_019_40760_x
crossref_primary_10_3389_fimmu_2019_03038
crossref_primary_10_3389_fonc_2021_622896
crossref_primary_10_3390_cancers13112724
crossref_primary_10_1007_s00262_021_02975_8
crossref_primary_10_1007_s12672_022_00567_1
crossref_primary_10_1111_imcb_12658
crossref_primary_10_1007_s00262_022_03217_1
crossref_primary_10_1007_s00262_021_03008_0
crossref_primary_10_1016_j_imlet_2023_08_005
crossref_primary_10_15789_1563_0625_TOI_3125
crossref_primary_10_1155_2022_1786395
Cites_doi 10.1038/bmt.2012.162
10.1159/000072714
10.1126/science.1068440
10.1158/1078-0432.CCR-15-1604
10.1016/j.semcancer.2007.07.003
10.1200/JCO.2014.57.3329
10.1016/j.bbmt.2016.08.008
10.1182/blood-2013-10-532531
10.1158/2326-6066.CIR-15-0118
10.3389/fphar.2015.00021
10.1158/2326-6066.CIR-15-0093-T
10.1371/journal.pone.0053611
10.4049/jimmunol.175.8.5095
10.1038/bjc.2014.35
10.1038/icb.2010.78
10.1038/srep21757
10.1172/jci45816
10.1182/blood-2014-02-556837
10.18632/oncotarget.8526
10.1056/NEJM198704093161502
10.1182/blood-2012-03-415364
10.1182/blood-2014-07-592881
10.1158/1078-0432.ccr-16-2981
10.1200/JCO.2009.24.4590
10.1002/ijc.11321
10.5966/sctm.2012-0084
10.1016/j.jcyt.2016.02.006
10.1111/j.1537-2995.2012.03764.x
10.1182/blood-2013-03-478255
10.3109/14653249.2010.515582
10.1182/blood-2011-01-329508
10.3389/fimmu.2017.00087
10.1007/s00262-012-1212-x
10.1159/000381524
10.1038/nri3370
10.1016/j.bbmt.2016.09.006
10.1016/j.jcyt.2013.06.017
10.1182/blood.V118.21.4035.4035
10.1038/mt.2014.50
10.18632/oncotarget.7470
10.1186/2051-1426-1-S1-P40
10.1111/j.1537-2995.2012.03724.x
10.1371/journal.pone.0020740
10.1016/j.bbmt.2014.01.031
10.1016/j.molonc.2013.12.001
10.1016/j.annpat.2015.11.004
10.1038/icb.2013.45
10.1073/pnas.95.9.5199
10.1056/NEJMra052638
10.1002/ijc.29686
10.3389/fimmu.2015.00097
10.1002/immu.200390014
10.1158/1078-0432.CCR-03-0683
10.1038/sj.leu.2403524
10.1002/eji.201444586
10.1158/1078-0432.CCR-15-1419
10.1182/asheducation-2013.1.247
10.1016/0167-5699(90)90097-S
10.1038/nrc2355
10.1080/14712598.2017.1271874
10.1038/icb.2013.98
10.1182/blood-2004-07-2974
10.1007/s13238-014-0059-7
10.1126/scitranslmed.aaf2341
10.1371/journal.pone.0123416
10.1016/j.it.2010.06.003
10.1182/blood.V94.1.333.413a31_333_339
10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.3.CO;2-M
10.1038/nri3175
10.1016/j.drudis.2015.02.008
10.1016/j.jcyt.2014.12.001
10.1111/bjh.14570
10.1182/blood-2013-12-542480
10.1182/blood.V98.12.3192
10.1182/blood-2005-03-0987
10.4161/mabs.28282
10.1073/pnas.1100354108
10.1016/S1471-4906(01)02060-9
10.1038/bmt.2009.304
10.1016/j.bbmt.2015.12.028
10.1084/jem.188.12.2375
10.1007/s00262-010-0904-3
10.1016/j.bbmt.2010.02.018
10.1016/j.bbmt.2016.04.009
10.1007/s00262-010-0896-z
10.1158/1078-0432.CCR-08-2810
10.1111/j.1365-2141.2008.07340.x
10.1186/1756-8722-6-1
10.1038/icb.2017.6
10.1038/icb.2013.95
10.1055/s-2005-872520
10.1158/2326-6066.CIR-15-0229
10.1038/ni.3470
10.1158/1078-0432.CCR-11-1347
10.1371/journal.pone.0096705
10.1089/scd.2011.0659
10.4161/onci.26527
10.3389/fimmu.2015.00368
10.1186/s13045-015-0227-0
10.1200/JCO.2013.52.0924
10.1007/s00262-016-1919-1
10.1097/CJI.0000000000000059
10.1371/journal.pone.0064384
10.3389/fimmu.2016.00091
10.1158/0008-5472.can-12-3558
10.1084/jem.187.5.813
10.1182/blood-2014-12-614636
10.1080/14653240802301872
10.1182/blood-2011-04-348409
10.1056/NEJM198512053132327
10.1182/blood-2008-06-165225
10.1016/S0169-5002(01)00292-6
10.1016/j.tips.2011.09.004
10.1371/journal.pone.0009221
10.1158/0008-5472.CAN-12-2357
10.1002/hep.23054
10.1016/j.ejca.2013.10.015
10.1016/j.celrep.2015.06.059
10.1111/j.1600-065X.2006.00445.x
10.1016/S1074-7613(00)80441-0
10.1016/j.jhep.2005.05.026
10.3389/fimmu.2015.00266
10.1016/S0065-2776(06)90004-2
10.1371/journal.pone.0030264
10.1371/journal.pone.0027351
10.1038/leu.2013.279
10.1158/0008-5472.can-09-1947
10.1016/j.clim.2015.10.001
10.1182/blood.V124.21.2320.2320
10.1002/pbc.25555
10.1016/j.jaci.2013.07.006
10.18632/oncotarget.5490
ContentType Journal Article
Copyright Copyright © 2017 Veluchamy, Kok, van der Vliet, Verheul, de Gruijl and Spanholtz. 2017 Veluchamy, Kok, van der Vliet, Verheul, de Gruijl and Spanholtz
Copyright_xml – notice: Copyright © 2017 Veluchamy, Kok, van der Vliet, Verheul, de Gruijl and Spanholtz. 2017 Veluchamy, Kok, van der Vliet, Verheul, de Gruijl and Spanholtz
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2017.00631
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_64f543aec174413db67dc06b1cfe3add
PMC5450018
28620386
10_3389_fimmu_2017_00631
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
ACXDI
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c528t-a6cfa75bf991ced40b13046eb663e66f0fa7c09e019448781d91916c1dfd48ed3
IEDL.DBID DOA
ISICitedReferencesCount 150
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000402338000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1664-3224
IngestDate Fri Oct 03 12:53:36 EDT 2025
Thu Aug 21 14:02:41 EDT 2025
Sun Aug 24 03:28:36 EDT 2025
Thu Jan 02 22:20:25 EST 2025
Sat Nov 29 03:12:40 EST 2025
Tue Nov 18 21:18:28 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords adoptive natural killer cell therapy
hematopoietic stem cell transplantation
natural killer cell combinatorial studies
allogeneic natural killer cells
natural killer cell biotech companies
autologous natural killer cells
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-a6cfa75bf991ced40b13046eb663e66f0fa7c09e019448781d91916c1dfd48ed3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Specialty section: This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology
Edited by: Gianfranco Pittari, Hamad Medical Corporation, Qatar
These authors have contributed equally to this work.
Reviewed by: Evelyn Ullrich, Goethe University Frankfurt, Germany; Bjarne Kuno Møller, Aarhus University Hospital, Denmark
OpenAccessLink https://doaj.org/article/64f543aec174413db67dc06b1cfe3add
PMID 28620386
PQID 1910793286
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_64f543aec174413db67dc06b1cfe3add
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5450018
proquest_miscellaneous_1910793286
pubmed_primary_28620386
crossref_primary_10_3389_fimmu_2017_00631
crossref_citationtrail_10_3389_fimmu_2017_00631
PublicationCentury 2000
PublicationDate 2017-05-31
PublicationDateYYYYMMDD 2017-05-31
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-31
  day: 31
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2017
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Parham (B13) 2013; 13
Luna (B1) 2017; 17
Passweg (B44) 2004; 18
Ito (B120) 2014; 22
Rizzieri (B48) 2010; 16
Schleypen (B16) 2003; 106
Stern (B52) 2013; 48
Chu (B94) 2014; 28
Burke (B22) 2010; 31
Bachanova (B64) 2014; 123
Rosario (B130) 2016; 22
Wang (B74) 2015; 6
Pegram (B8) 2011; 89
Villegas (B21) 2002; 35
Ng (B106) 2005; 106
Rhode (B126) 2016; 4
Mamessier (B28) 2011; 121
Wu (B35) 2006; 90
Miller (B50) 2005; 105
Klingemann (B97) 2016; 7
Ogura (B76) 2014; 32
Torikai (B104) 2013; 122
Delconte (B105) 2016; 17
Copelan (B51) 2006; 354
Hoechst (B24) 2009; 50
Veluchamy (B115) 2017; 8
Woll (B107) 2005; 175
Steel (B121) 2012; 33
Ishigami (B20) 2000; 88
Kottaridis (B66) 2015; 10
Ghiringhelli (B23) 2006; 214
Shaim (B110) 2015; 17
Killig (B55) 2014; 44
Rothe (B84) 2015; 125
Roccaro (B134) 2015; 12
Borcherding (B99) 2014; 5
Frei (B133) 2011; 118
Ruggeri (B39) 1999; 94
Kondo (B19) 2003; 20
Tonn (B43) 2013; 15
Bachanova (B62) 2010; 59
Szmania (B65) 2015; 38
Sahm (B92) 2012; 61
Ljunggren (B12) 1990; 11
Parkhurst (B30) 2011; 17
Zhang (B91) 2013; 91
Marasca (B135) 2014; 123
Lee (B57) 2016; 22
Martin (B85) 2014
Goede (B77) 2015; 38
Kontermann (B82) 2015; 20
Kim (B129) 2016; 7
Chou (B136) 2010; 70
Antin (B37) 2011; 117
Iliopoulou (B60) 2010; 59
Leibson (B9) 1997; 6
Shah (B56) 2015; 125
Dolstra (B73) 2017
Spanholtz (B41) 2011; 6
Fehniger (B131) 2014; 124
Denman (B123) 2012; 7
Yang (B69) 2016; 4
Knorr (B109) 2013; 2
Glienke (B89) 2015; 6
Carlsten (B103) 2015; 6
Klingemann (B53) 2013; 53
Fan (B83) 2015; 8
Geller (B33) 2011; 13
Arai (B42) 2008; 10
Yoon (B47) 2010; 45
Zamai (B10) 1998; 188
Boissel (B96) 2013; 2
Imamura (B122) 2014; 124
Borrego (B7) 1998; 187
Ochoa (B81) 2017
Gomes-Giacoia (B128) 2014; 9
de Andrade (B5) 2014; 92
Gill (B26) 2012; 119
Krasnova (B11) 2015
Oyer (B124) 2016; 18
Kruse (B6) 2014; 92
Woll (B108) 2009; 113
Delord (B80) 2014; 50
Chang (B100) 2013; 73
Miller (B119) 2013; 2013
Bauernhofer (B29) 2003; 33
Kamiya (B101) 2016; 4
Shaffer (B70) 2016; 22
Rosenberg (B31) 1985; 313
Chen (B93) 2016; 7
Rosenberg (B32) 2008; 8
Jiang (B95) 2014; 8
Choi (B54) 2014; 20
Ruggeri (B38) 2002; 295
Romee (B72) 2016; 8
Cany (B112) 2013; 8
Schafer (B27) 2015; 6
Xu (B125) 2013; 73
Mathios (B127) 2016; 138
Veluchamy (B114) 2017; 66
Altvater (B90) 2009; 15
Rubnitz (B61) 2010; 28
Oppenheim (B79) 2014; 110
Adam (B98) 2016; 36
Conlon (B118) 2015; 33
Shi (B46) 2008; 143
Gooden (B88) 2011; 108
Sola (B86) 2013; 1
Lee (B15) 1998; 95
Cooper (B2) 2001; 22
Campbell (B3) 2013; 132
Hsia (B18) 2005; 28
Rouas-Freiss (B14) 2007; 17
Levy (B87) 2008; 32
Spanholtz (B111) 2010; 5
Mellor (B75) 2013; 6
Krause (B132) 2004; 10
Cheney (B78) 2014; 6
Rubnitz (B67) 2015; 62
Lehmann (B113) 2012; 21
Curti (B63) 2011; 118
West (B117) 1987; 316
Jinushi (B17) 2005; 43
Ho (B36) 2001; 98
Rosenberg (B116) 2000; 6
Gabrilovich (B25) 2012; 12
Minculescu (B34) 2016; 22
Koepsell (B40) 2013; 53
Koehl (B45) 2005; 217
Curti (B71) 2016; 22
Zhang (B4) 2015; 6
Torikai (B102) 2016; 6
Lim (B68) 2013; 8
Shah (B59) 2017; 177
Choi (B58) 2016; 22
Brehm (B49) 2011; 6
26113846 - Front Immunol. 2015 Jun 10;6:266
26062124 - PLoS One. 2015 Jun 10;10 (6):e0123416
22571679 - Stem Cells Dev. 2012 Nov 1;21(16):2926-38
26778219 - Ann Pathol. 2016 Jan;36(1):94-102
23302231 - Cancer Res. 2013 Mar 15;73(6):1777-86
15914555 - Blood. 2005 Sep 1;106(5):1601-3
24895051 - Eur J Immunol. 2014 Sep;44(9):2822-34
26787753 - Clin Cancer Res. 2016 Apr 15;22(8):1914-21
21841316 - J Clin Invest. 2011 Sep;121(9):3609-22
24343663 - Immunol Cell Biol. 2014 Mar;92(3):237-44
18354418 - Nat Rev Cancer. 2008 Apr;8(4):299-308
20169160 - PLoS One. 2010 Feb 15;5(2):e9221
19638467 - Clin Cancer Res. 2009 Aug 1;15(15):4857-66
21698239 - PLoS One. 2011;6(6):e20740
24526776 - Blood. 2014 Feb 13;123(7):952-3
22437938 - Nat Rev Immunol. 2012 Mar 22;12(4):253-68
3493433 - N Engl J Med. 1987 Apr 9;316(15):898-905
16168521 - J Hepatol. 2005 Dec;43(6):1013-20
26174883 - Int J Cancer. 2016 Jan 1;138(1):187-94
23326467 - PLoS One. 2013;8(1):e53611
20680271 - Cancer Immunol Immunother. 2010 Nov;59(11):1739-44
28220124 - Front Immunol. 2017 Feb 06;8:87
12918068 - Int J Cancer. 2003 Oct 10;106(6):905-12
27050072 - Oncotarget. 2016 May 10;7(19):27764-77
9560253 - Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
23755121 - PLoS One. 2013 Jun 05;8(6):e64384
23644531 - Cancer Res. 2013 May 15;73(10):3075-86
10381530 - Blood. 1999 Jul 1;94(1):333-9
10685650 - Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7
26772158 - Biol Blood Marrow Transplant. 2016 Apr;22(4):705-9
24896845 - PLoS One. 2014 Jun 04;9(6):e96705
15457184 - Leukemia. 2004 Nov;18(11):1835-8
11896281 - Science. 2002 Mar 15;295(5562):2097-100
20188202 - Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14
27213690 - Nat Immunol. 2016 Jul;17 (7):816-24
26787822 - Cancer Immunol Res. 2016 Mar;4(3):215-24
19881555 - Bone Marrow Transplant. 2010 Jun;45(6):1038-46
20068163 - Cancer Res. 2010 Jan 15;70(2):440-6
22096557 - PLoS One. 2011;6(11):e27351
22032984 - Trends Pharmacol Sci. 2012 Jan;33(1):35-41
18836917 - Cytotherapy. 2008;10(6):625-32
24067492 - Leukemia. 2014 Apr;28(4):917-27
24752542 - Protein Cell. 2014 Jul;5(7):496-502
24262587 - Eur J Cancer. 2014 Feb;50(3):496-505
20567250 - Immunol Cell Biol. 2011 Feb;89(2):216-24
10649250 - Cancer. 2000 Feb 1;88(3):577-83
27014270 - Front Immunol. 2016 Mar 14;7:91
16086548 - Chang Gung Med J. 2005 May;28(5):335-40
24366519 - Immunol Cell Biol. 2014 Mar;92(3):221-9
25925135 - Pediatr Blood Cancer. 2015 Aug;62(8):1468-72
27197065 - Cancer Immunol Res. 2016 Jul;4(7):574-81
12594840 - Eur J Immunol. 2003 Jan;33(1):119-24
27960589 - Expert Opin Biol Ther. 2017 Mar;17 (3):313-324
2201309 - Immunol Today. 1990 Jul;11(7):237-44
22310931 - Cancer Immunol Immunother. 2012 Sep;61(9):1451-61
22738379 - Transfusion. 2013 Feb;53(2):412-8; quiz 411
25527863 - Cytotherapy. 2015 Jan;17(1):1-2
22670662 - Transfusion. 2013 Feb;53(2):404-10
22279576 - PLoS One. 2012;7(1):e30264
27530969 - Biol Blood Marrow Transplant. 2016 Nov;22(11):2065-2076
15632206 - Blood. 2005 Apr 15;105(8):3051-7
25887777 - Blood. 2015 Jun 25;125(26):4024-31
26392410 - Oncotarget. 2015 Sep 8;6(26):21797-8
9480992 - J Exp Med. 1998 Mar 2;187(5):813-8
27655849 - Sci Transl Med. 2016 Sep 21;8(357):357ra123
3903508 - N Engl J Med. 1985 Dec 5;313(23):1485-92
27090958 - Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-8
24319187 - Hematology Am Soc Hematol Educ Program. 2013;2013:247-53
27059202 - Cytotherapy. 2016 May;18(5):653-63
24686272 - Mol Ther. 2014 Jul;22(7):1388-95
27783105 - Cancer Immunol Immunother. 2017 Jan;66(1):51-61
25403209 - J Clin Oncol. 2015 Jan 1;33(1):74-82
23741009 - Blood. 2013 Aug 22;122(8):1341-9
22941380 - Bone Marrow Transplant. 2013 Mar;48(3):433-8
23906377 - J Allergy Clin Immunol. 2013 Sep;132(3):536-44
24616310 - J Clin Oncol. 2014 Apr 10;32(11):1157-63
24100387 - Immunol Cell Biol. 2013 Nov-Dec;91(10):615-24
20655806 - Trends Immunol. 2010 Sep;31(9):339-45
21844012 - Clin Cancer Res. 2011 Oct 1;17(19):6287-97
12900537 - Dig Surg. 2003;20(5):445-51
23286345 - J Hematol Oncol. 2013 Jan 04;6:1
16641398 - N Engl J Med. 2006 Apr 27;354(17):1813-26
26511282 - Cancer Immunol Res. 2016 Jan;4(1):49-60
25452614 - Blood. 2015 Jan 29;125(5):784-92
26476139 - Clin Immunol. 2017 Apr;177:50-59
11698225 - Trends Immunol. 2001 Nov;22(11):633-40
24719405 - Blood. 2014 Jun 19;123(25):3855-63
24525278 - Biol Blood Marrow Transplant. 2014 May;20(5):696-704
24388357 - Mol Oncol. 2014 Mar;8(2):297-310
23334245 - Nat Rev Immunol. 2013 Feb;13(2):133-44
11719354 - Blood. 2001 Dec 1;98(12):3192-204
20849361 - Cytotherapy. 2011 Jan;13(1):98-107
15173076 - Clin Cancer Res. 2004 Jun 1;10(11):3699-707
21659553 - Blood. 2011 Jun 9;117(23):6061-2
16210613 - J Immunol. 2005 Oct 15;175(8):5095-103
20703455 - Cancer Immunol Immunother. 2010 Dec;59(12):1781-9
9208838 - Immunity. 1997 Jun;6(6):655-61
28280089 - Clin Cancer Res. 2017 Mar 9;:null
26284063 - Front Immunol. 2015 Jul 27;6:368
22544698 - Blood. 2012 Jun 14;119(24):5758-68
24094496 - Cytotherapy. 2013 Dec;15(12):1563-70
11750709 - Lung Cancer. 2002 Jan;35(1):23-8
17100888 - Immunol Rev. 2006 Dec;214:229-38
18950462 - Br J Haematol. 2008 Dec;143(5):641-53
18292941 - Int J Oncol. 2008 Mar;32(3):633-41
24404423 - Oncoimmunology. 2013 Oct 1;2(10):e26527
9858524 - J Exp Med. 1998 Dec 21;188(12):2375-80
26910920 - Oncotarget. 2016 Mar 29;7(13):16130-45
16307421 - Klin Padiatr. 2005 Nov-Dec;217(6):345-50
25728220 - Drug Discov Today. 2015 Jul;20(7):838-47
25006133 - Blood. 2014 Aug 14;124(7):1081-8
16730263 - Adv Immunol. 2006;90:133-73
24496456 - Br J Cancer. 2014 Mar 4;110(5):1221-7
21791425 - Blood. 2011 Sep 22;118(12):3273-9
19551844 - Hepatology. 2009 Sep;50(3):799-807
26902653 - Sci Rep. 2016 Feb 23;6:21757
25729364 - Front Pharmacol. 2015 Feb 12;6:21
25788898 - Front Immunol. 2015 Mar 04;6:97
28138156 - Immunol Cell Biol. 2017 Apr;95(4):347-355
26423796 - Clin Cancer Res. 2016 Feb 1;22(3):596-608
24594909 - MAbs. 2014 May-Jun;6(3):749-55
21670276 - Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10656-61
26190113 - Cell Rep. 2015 Jul 28;12(4):622-35
25877943 - Oncol Res Treat. 2015;38(4):185-92
20085940 - J Clin Oncol. 2010 Feb 20;28(6):955-9
19365083 - Blood. 2009 Jun 11;113(24):6094-101
28295190 - Br J Haematol. 2017 May;177(3):457-466
23515118 - Stem Cells Transl Med. 2013 Apr;2(4):274-83
27664326 - Biol Blood Marrow Transplant. 2016 Dec;22(12 ):2187-2193
25415285 - J Immunother. 2015 Jan;38(1):24-36
26692321 - J Hematol Oncol. 2015 Dec 21;8:130
17881247 - Semin Cancer Biol. 2007 Dec;17(6):413-21
References_xml – volume: 48
  start-page: 433
  year: 2013
  ident: B52
  article-title: Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2012.162
– volume: 20
  start-page: 445
  year: 2003
  ident: B19
  article-title: Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer
  publication-title: Dig Surg
  doi: 10.1159/000072714
– volume: 295
  start-page: 2097
  year: 2002
  ident: B38
  article-title: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
  publication-title: Science
  doi: 10.1126/science.1068440
– volume: 22
  start-page: 1914
  year: 2016
  ident: B71
  article-title: Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1604
– volume: 17
  start-page: 413
  year: 2007
  ident: B14
  article-title: Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2007.07.003
– volume: 33
  start-page: 74
  year: 2015
  ident: B118
  article-title: Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.3329
– volume: 22
  start-page: 2065
  year: 2016
  ident: B58
  article-title: Donor-derived natural killer cell infusion after human leukocyte antigen-haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2016.08.008
– volume: 123
  start-page: 3855
  year: 2014
  ident: B64
  article-title: Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
  publication-title: Blood
  doi: 10.1182/blood-2013-10-532531
– volume: 4
  start-page: 215
  year: 2016
  ident: B69
  article-title: Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-15-0118
– volume: 6
  start-page: 21
  year: 2015
  ident: B89
  article-title: Advantages and applications of CAR-expressing natural killer cells
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2015.00021
– volume: 4
  start-page: 49
  year: 2016
  ident: B126
  article-title: Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-15-0093-T
– volume: 8
  start-page: e53611
  year: 2013
  ident: B68
  article-title: GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0053611
– volume: 175
  start-page: 5095
  year: 2005
  ident: B107
  article-title: Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity
  publication-title: J Immunol
  doi: 10.4049/jimmunol.175.8.5095
– volume: 110
  start-page: 1221
  year: 2014
  ident: B79
  article-title: Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.35
– volume: 89
  start-page: 216
  year: 2011
  ident: B8
  article-title: Activating and inhibitory receptors of natural killer cells
  publication-title: Immunol Cell Biol
  doi: 10.1038/icb.2010.78
– volume: 6
  start-page: 21757
  year: 2016
  ident: B102
  article-title: Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application
  publication-title: Sci Rep
  doi: 10.1038/srep21757
– volume: 121
  start-page: 3609
  year: 2011
  ident: B28
  article-title: Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
  publication-title: J Clin Invest
  doi: 10.1172/jci45816
– volume: 124
  start-page: 1081
  year: 2014
  ident: B122
  article-title: Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
  publication-title: Blood
  doi: 10.1182/blood-2014-02-556837
– volume: 7
  start-page: 27764
  year: 2016
  ident: B93
  article-title: A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8526
– volume: 316
  start-page: 898
  year: 1987
  ident: B117
  article-title: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198704093161502
– volume: 119
  start-page: 5758
  year: 2012
  ident: B26
  article-title: Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
  publication-title: Blood
  doi: 10.1182/blood-2012-03-415364
– volume: 125
  start-page: 784
  year: 2015
  ident: B56
  article-title: Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood-2014-07-592881
– year: 2017
  ident: B73
  article-title: Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-16-2981
– volume: 28
  start-page: 955
  year: 2010
  ident: B61
  article-title: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.4590
– volume: 106
  start-page: 905
  year: 2003
  ident: B16
  article-title: Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11321
– volume: 2
  start-page: 274
  year: 2013
  ident: B109
  article-title: Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy
  publication-title: Stem Cells Transl Med
  doi: 10.5966/sctm.2012-0084
– volume: 18
  start-page: 653
  year: 2016
  ident: B124
  article-title: Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2016.02.006
– volume: 53
  start-page: 412
  year: 2013
  ident: B53
  article-title: Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions
  publication-title: Transfusion
  doi: 10.1111/j.1537-2995.2012.03764.x
– volume: 122
  start-page: 1341
  year: 2013
  ident: B104
  article-title: Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
  publication-title: Blood
  doi: 10.1182/blood-2013-03-478255
– volume: 13
  start-page: 98
  year: 2011
  ident: B33
  article-title: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
  publication-title: Cytotherapy
  doi: 10.3109/14653249.2010.515582
– volume: 118
  start-page: 3273
  year: 2011
  ident: B63
  article-title: Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
  publication-title: Blood
  doi: 10.1182/blood-2011-01-329508
– volume: 8
  start-page: 87
  year: 2017
  ident: B115
  article-title: In vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.00087
– volume: 61
  start-page: 1451
  year: 2012
  ident: B92
  article-title: Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-012-1212-x
– volume: 38
  start-page: 185
  year: 2015
  ident: B77
  article-title: Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin’s lymphomas: a glycoengineered type II CD20 antibody
  publication-title: Oncol Res Treat
  doi: 10.1159/000381524
– volume: 13
  start-page: 133
  year: 2013
  ident: B13
  article-title: Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3370
– volume: 22
  start-page: 2187
  year: 2016
  ident: B34
  article-title: Early natural killer cell reconstitution predicts overall survival in T cell–replete allogeneic hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2016.09.006
– volume-title: Non-Natural MIC Proteins
  year: 2014
  ident: B85
– volume: 15
  start-page: 1563
  year: 2013
  ident: B43
  article-title: Treatment of patients with advanced cancer with the natural killer cell line NK-92
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2013.06.017
– volume: 118
  start-page: 4035
  year: 2011
  ident: B133
  article-title: Nicotinamide, a form of vitamin B3, promotes expansion of natural killer cells that display increased in vivo survival and cytotoxic activity
  publication-title: Blood
  doi: 10.1182/blood.V118.21.4035.4035
– volume: 22
  start-page: 1388
  year: 2014
  ident: B120
  article-title: Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers
  publication-title: Mol Ther
  doi: 10.1038/mt.2014.50
– volume: 7
  start-page: 16130
  year: 2016
  ident: B129
  article-title: IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7470
– volume: 1
  start-page: 40
  year: 2013
  ident: B86
  article-title: Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model
  publication-title: J Immunother Cancer
  doi: 10.1186/2051-1426-1-S1-P40
– volume: 53
  start-page: 404
  year: 2013
  ident: B40
  article-title: Natural killer cells: a review of manufacturing and clinical utility
  publication-title: Transfusion
  doi: 10.1111/j.1537-2995.2012.03724.x
– volume: 6
  start-page: e20740
  year: 2011
  ident: B41
  article-title: Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020740
– volume: 20
  start-page: 696
  year: 2014
  ident: B54
  article-title: Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2014.01.031
– volume: 8
  start-page: 297
  year: 2014
  ident: B95
  article-title: Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2013.12.001
– volume: 36
  start-page: 94
  year: 2016
  ident: B98
  article-title: [PD-L1 expression: an emerging biomarker in non-small cell lung cancer]
  publication-title: Ann Pathol
  doi: 10.1016/j.annpat.2015.11.004
– volume: 91
  start-page: 615
  year: 2013
  ident: B91
  article-title: Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody
  publication-title: Immunol Cell Biol
  doi: 10.1038/icb.2013.45
– volume: 95
  start-page: 5199
  year: 1998
  ident: B15
  article-title: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.95.9.5199
– volume: 354
  start-page: 1813
  year: 2006
  ident: B51
  article-title: Hematopoietic Stem-Cell Transplantation
  publication-title: New Engl J Med
  doi: 10.1056/NEJMra052638
– volume: 138
  start-page: 187
  year: 2016
  ident: B127
  article-title: Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29686
– volume: 6
  start-page: 97
  year: 2015
  ident: B4
  article-title: NKG2D ligands in tumor immunity: two sides of a coin
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2015.00097
– volume: 33
  start-page: 119
  year: 2003
  ident: B29
  article-title: Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer
  publication-title: Eur J Immunol
  doi: 10.1002/immu.200390014
– volume: 10
  start-page: 3699
  year: 2004
  ident: B132
  article-title: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-03-0683
– volume: 18
  start-page: 1835
  year: 2004
  ident: B44
  article-title: Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403524
– volume: 44
  start-page: 2822
  year: 2014
  ident: B55
  article-title: Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201444586
– volume: 22
  start-page: 596
  year: 2016
  ident: B130
  article-title: The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1419
– volume: 2013
  start-page: 247
  year: 2013
  ident: B119
  article-title: Therapeutic applications: natural killer cells in the clinic
  publication-title: Hematology Am Soc Hematol Educ Program
  doi: 10.1182/asheducation-2013.1.247
– volume: 11
  start-page: 237
  year: 1990
  ident: B12
  article-title: In search of the ‘missing self’: MHC molecules and NK cell recognition
  publication-title: Immunol Today
  doi: 10.1016/0167-5699(90)90097-S
– volume: 8
  start-page: 299
  year: 2008
  ident: B32
  article-title: Adoptive cell transfer: a clinical path to effective cancer immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2355
– volume: 17
  start-page: 313
  year: 2017
  ident: B1
  article-title: Targeting cancer stem cells with natural killer cell immunotherapy
  publication-title: Expert Opin Biol Ther
  doi: 10.1080/14712598.2017.1271874
– volume: 92
  start-page: 221
  year: 2014
  ident: B6
  article-title: Natural cytotoxicity receptors and their ligands
  publication-title: Immunol Cell Biol
  doi: 10.1038/icb.2013.98
– volume: 105
  start-page: 3051
  year: 2005
  ident: B50
  article-title: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2974
– volume: 5
  start-page: 496
  year: 2014
  ident: B99
  article-title: ROR1, an embryonic protein with an emerging role in cancer biology
  publication-title: Protein Cell
  doi: 10.1007/s13238-014-0059-7
– volume: 8
  start-page: ra123
  year: 2016
  ident: B72
  article-title: Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aaf2341
– volume: 10
  start-page: e0123416
  year: 2015
  ident: B66
  article-title: Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0123416
– volume: 31
  start-page: 339
  year: 2010
  ident: B22
  article-title: New views on natural killer cell-based immunotherapy for melanoma treatment
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2010.06.003
– volume: 94
  start-page: 333
  year: 1999
  ident: B39
  article-title: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood.V94.1.333.413a31_333_339
– volume: 88
  start-page: 577
  year: 2000
  ident: B20
  article-title: Prognostic value of intratumoral natural killer cells in gastric carcinoma
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.3.CO;2-M
– volume: 12
  start-page: 253
  year: 2012
  ident: B25
  article-title: Coordinated regulation of myeloid cells by tumours
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3175
– volume: 20
  start-page: 838
  year: 2015
  ident: B82
  article-title: Bispecific antibodies
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2015.02.008
– volume: 17
  start-page: 1
  year: 2015
  ident: B110
  article-title: Cord blood: a promising source of allogeneic natural killer cells for immunotherapy
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2014.12.001
– volume: 177
  start-page: 457
  year: 2017
  ident: B59
  article-title: Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
  publication-title: Br J Haematol
  doi: 10.1111/bjh.14570
– volume: 123
  start-page: 952
  year: 2014
  ident: B135
  article-title: NOX-A12: mobilizing CLL away from home
  publication-title: Blood
  doi: 10.1182/blood-2013-12-542480
– volume: 98
  start-page: 3192
  year: 2001
  ident: B36
  article-title: The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood.V98.12.3192
– volume: 6
  start-page: S2
  year: 2000
  ident: B116
  article-title: Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
  publication-title: Cancer J Sci Am
– volume: 106
  start-page: 1601
  year: 2005
  ident: B106
  article-title: Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation
  publication-title: Blood
  doi: 10.1182/blood-2005-03-0987
– volume: 6
  start-page: 749
  year: 2014
  ident: B78
  article-title: Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia
  publication-title: mAbs
  doi: 10.4161/mabs.28282
– volume: 108
  start-page: 10656
  year: 2011
  ident: B88
  article-title: HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1100354108
– volume: 22
  start-page: 633
  year: 2001
  ident: B2
  article-title: The biology of human natural killer-cell subsets
  publication-title: Trends Immunol
  doi: 10.1016/S1471-4906(01)02060-9
– volume: 45
  start-page: 1038
  year: 2010
  ident: B47
  article-title: Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2009.304
– volume: 22
  start-page: 705
  year: 2016
  ident: B70
  article-title: Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2015.12.028
– volume: 188
  start-page: 2375
  year: 1998
  ident: B10
  article-title: Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells
  publication-title: J Exp Med
  doi: 10.1084/jem.188.12.2375
– volume: 28
  start-page: 335
  year: 2005
  ident: B18
  article-title: Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma
  publication-title: Chang Gung Med J
– volume: 59
  start-page: 1781
  year: 2010
  ident: B60
  article-title: A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-010-0904-3
– volume: 16
  start-page: 1107
  year: 2010
  ident: B48
  article-title: Natural killer cell enriched donor lymphocyte infusions from a 3-6/6 HLA matched family member following non-myeloablative allogeneic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.02.018
– volume: 22
  start-page: 1290
  year: 2016
  ident: B57
  article-title: Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2016.04.009
– volume: 59
  start-page: 1739
  year: 2010
  ident: B62
  article-title: Allogeneic natural killer cells for refractory lymphoma
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-010-0896-z
– volume: 15
  start-page: 4857
  year: 2009
  ident: B90
  article-title: 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-2810
– volume: 143
  start-page: 641
  year: 2008
  ident: B46
  article-title: Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2008.07340.x
– volume: 6
  start-page: 1
  year: 2013
  ident: B75
  article-title: A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-6-1
– year: 2017
  ident: B81
  article-title: Antibody-dependent cell cytotoxicity (ADCC): immunotherapy strategies enhancing effector NK cells
  publication-title: Immunol Cell Biol
  doi: 10.1038/icb.2017.6
– volume: 92
  start-page: 237
  year: 2014
  ident: B5
  article-title: DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins
  publication-title: Immunol Cell Biol
  doi: 10.1038/icb.2013.95
– volume: 217
  start-page: 345
  year: 2005
  ident: B45
  article-title: Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children
  publication-title: Klin Padiatr
  doi: 10.1055/s-2005-872520
– volume: 4
  start-page: 574
  year: 2016
  ident: B101
  article-title: Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-15-0229
– volume: 17
  start-page: 816
  year: 2016
  ident: B105
  article-title: CIS is a potent checkpoint in NK cell-mediated tumor immunity
  publication-title: Nat Immunol
  doi: 10.1038/ni.3470
– volume: 17
  start-page: 6287
  year: 2011
  ident: B30
  article-title: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-1347
– volume: 32
  start-page: 633
  year: 2008
  ident: B87
  article-title: Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer
  publication-title: Int J Oncol
– volume: 9
  start-page: e96705
  year: 2014
  ident: B128
  article-title: Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0096705
– volume: 21
  start-page: 2926
  year: 2012
  ident: B113
  article-title: Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2011.0659
– volume: 2
  start-page: e26527
  year: 2013
  ident: B96
  article-title: Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
  publication-title: Oncoimmunology
  doi: 10.4161/onci.26527
– volume: 6
  start-page: 368
  year: 2015
  ident: B74
  article-title: NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2015.00368
– volume: 8
  start-page: 130
  year: 2015
  ident: B83
  article-title: Bispecific antibodies and their applications
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-015-0227-0
– volume: 32
  start-page: 1157
  year: 2014
  ident: B76
  article-title: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.52.0924
– volume: 66
  start-page: 51
  year: 2017
  ident: B114
  article-title: High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-016-1919-1
– volume: 38
  start-page: 24
  year: 2015
  ident: B65
  article-title: Ex vivo expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients
  publication-title: J Immunother
  doi: 10.1097/CJI.0000000000000059
– volume: 8
  start-page: e64384
  year: 2013
  ident: B112
  article-title: Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rgnull mice
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0064384
– volume: 7
  start-page: 91
  year: 2016
  ident: B97
  article-title: Natural killer cells for immunotherapy–advantages of the NK-92 cell line over blood NK cells
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00091
– volume: 73
  start-page: 1777
  year: 2013
  ident: B100
  article-title: A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.can-12-3558
– volume: 187
  start-page: 813
  year: 1998
  ident: B7
  article-title: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis
  publication-title: J Exp Med
  doi: 10.1084/jem.187.5.813
– volume: 125
  start-page: 4024
  year: 2015
  ident: B84
  article-title: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2014-12-614636
– volume: 10
  start-page: 625
  year: 2008
  ident: B42
  article-title: Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
  publication-title: Cytotherapy
  doi: 10.1080/14653240802301872
– volume: 117
  start-page: 6061
  year: 2011
  ident: B37
  article-title: T-cell depletion in GVHD: less is more?
  publication-title: Blood
  doi: 10.1182/blood-2011-04-348409
– volume: 313
  start-page: 1485
  year: 1985
  ident: B31
  article-title: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198512053132327
– volume: 113
  start-page: 6094
  year: 2009
  ident: B108
  article-title: Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
  publication-title: Blood
  doi: 10.1182/blood-2008-06-165225
– volume: 35
  start-page: 23
  year: 2002
  ident: B21
  article-title: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/S0169-5002(01)00292-6
– volume: 33
  start-page: 35
  year: 2012
  ident: B121
  article-title: Interleukin-15 biology and its therapeutic implications in cancer
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2011.09.004
– volume: 5
  start-page: e9221
  year: 2010
  ident: B111
  article-title: High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0009221
– volume: 73
  start-page: 3075
  year: 2013
  ident: B125
  article-title: Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor α/Fc fusion complex in syngeneic murine models of multiple myeloma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-2357
– volume: 50
  start-page: 799
  year: 2009
  ident: B24
  article-title: Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
  publication-title: Hepatology
  doi: 10.1002/hep.23054
– volume: 50
  start-page: 496
  year: 2014
  ident: B80
  article-title: Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.10.015
– volume: 12
  start-page: 622
  year: 2015
  ident: B134
  article-title: CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal transition-like transcriptional activation
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2015.06.059
– volume: 214
  start-page: 229
  year: 2006
  ident: B23
  article-title: The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2006.00445.x
– volume: 6
  start-page: 655
  year: 1997
  ident: B9
  article-title: Signal transduction during natural killer cell activation: inside the mind of a killer
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80441-0
– volume: 43
  start-page: 1013
  year: 2005
  ident: B17
  article-title: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2005.05.026
– volume: 6
  start-page: 266
  year: 2015
  ident: B103
  article-title: Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2015.00266
– volume: 90
  start-page: 133
  year: 2006
  ident: B35
  article-title: Induction of tumor immunity following allogeneic stem cell transplantation
  publication-title: Adv Immunol
  doi: 10.1016/S0065-2776(06)90004-2
– volume: 7
  start-page: e30264
  year: 2012
  ident: B123
  article-title: Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0030264
– volume: 6
  start-page: e27351
  year: 2011
  ident: B49
  article-title: IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0027351
– volume: 28
  start-page: 917
  year: 2014
  ident: B94
  article-title: CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
  publication-title: Leukemia
  doi: 10.1038/leu.2013.279
– volume: 70
  start-page: 440
  year: 2010
  ident: B136
  article-title: Drug combination studies and their synergy quantification using the Chou-Talalay method
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.can-09-1947
– year: 2015
  ident: B11
  article-title: Bench to bedside: NK cells and control of metastasis
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2015.10.001
– volume: 124
  start-page: 2320
  year: 2014
  ident: B131
  article-title: Preliminary results of a phase 1/2 clinical trial of Cndo-109-activated allogeneic natural killer cells in high risk acute myelogenous leukemia patients in first complete remission
  publication-title: Blood
  doi: 10.1182/blood.V124.21.2320.2320
– volume: 62
  start-page: 1468
  year: 2015
  ident: B67
  article-title: Natural killer cell therapy in children with relapsed leukemia
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.25555
– volume: 132
  start-page: 536
  year: 2013
  ident: B3
  article-title: NK cell biology: an update and future directions
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2013.07.006
– volume: 6
  start-page: 21797
  year: 2015
  ident: B27
  article-title: NK cell exhaustion: bad news for chronic disease?
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5490
– reference: 24594909 - MAbs. 2014 May-Jun;6(3):749-55
– reference: 18836917 - Cytotherapy. 2008;10(6):625-32
– reference: 25527863 - Cytotherapy. 2015 Jan;17(1):1-2
– reference: 24526776 - Blood. 2014 Feb 13;123(7):952-3
– reference: 21670276 - Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10656-61
– reference: 22941380 - Bone Marrow Transplant. 2013 Mar;48(3):433-8
– reference: 26392410 - Oncotarget. 2015 Sep 8;6(26):21797-8
– reference: 21659553 - Blood. 2011 Jun 9;117(23):6061-2
– reference: 15632206 - Blood. 2005 Apr 15;105(8):3051-7
– reference: 26423796 - Clin Cancer Res. 2016 Feb 1;22(3):596-608
– reference: 21844012 - Clin Cancer Res. 2011 Oct 1;17(19):6287-97
– reference: 26284063 - Front Immunol. 2015 Jul 27;6:368
– reference: 23515118 - Stem Cells Transl Med. 2013 Apr;2(4):274-83
– reference: 27014270 - Front Immunol. 2016 Mar 14;7:91
– reference: 25452614 - Blood. 2015 Jan 29;125(5):784-92
– reference: 25925135 - Pediatr Blood Cancer. 2015 Aug;62(8):1468-72
– reference: 24343663 - Immunol Cell Biol. 2014 Mar;92(3):237-44
– reference: 26113846 - Front Immunol. 2015 Jun 10;6:266
– reference: 25415285 - J Immunother. 2015 Jan;38(1):24-36
– reference: 26902653 - Sci Rep. 2016 Feb 23;6:21757
– reference: 20169160 - PLoS One. 2010 Feb 15;5(2):e9221
– reference: 15173076 - Clin Cancer Res. 2004 Jun 1;10(11):3699-707
– reference: 25877943 - Oncol Res Treat. 2015;38(4):185-92
– reference: 9560253 - Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
– reference: 16730263 - Adv Immunol. 2006;90:133-73
– reference: 22310931 - Cancer Immunol Immunother. 2012 Sep;61(9):1451-61
– reference: 24262587 - Eur J Cancer. 2014 Feb;50(3):496-505
– reference: 24094496 - Cytotherapy. 2013 Dec;15(12):1563-70
– reference: 23302231 - Cancer Res. 2013 Mar 15;73(6):1777-86
– reference: 17881247 - Semin Cancer Biol. 2007 Dec;17(6):413-21
– reference: 18354418 - Nat Rev Cancer. 2008 Apr;8(4):299-308
– reference: 26778219 - Ann Pathol. 2016 Jan;36(1):94-102
– reference: 23326467 - PLoS One. 2013;8(1):e53611
– reference: 24388357 - Mol Oncol. 2014 Mar;8(2):297-310
– reference: 23644531 - Cancer Res. 2013 May 15;73(10):3075-86
– reference: 25729364 - Front Pharmacol. 2015 Feb 12;6:21
– reference: 25788898 - Front Immunol. 2015 Mar 04;6:97
– reference: 26511282 - Cancer Immunol Res. 2016 Jan;4(1):49-60
– reference: 19881555 - Bone Marrow Transplant. 2010 Jun;45(6):1038-46
– reference: 22670662 - Transfusion. 2013 Feb;53(2):404-10
– reference: 21791425 - Blood. 2011 Sep 22;118(12):3273-9
– reference: 23334245 - Nat Rev Immunol. 2013 Feb;13(2):133-44
– reference: 27213690 - Nat Immunol. 2016 Jul;17 (7):816-24
– reference: 26787753 - Clin Cancer Res. 2016 Apr 15;22(8):1914-21
– reference: 25403209 - J Clin Oncol. 2015 Jan 1;33(1):74-82
– reference: 24319187 - Hematology Am Soc Hematol Educ Program. 2013;2013:247-53
– reference: 28138156 - Immunol Cell Biol. 2017 Apr;95(4):347-355
– reference: 20703455 - Cancer Immunol Immunother. 2010 Dec;59(12):1781-9
– reference: 27655849 - Sci Transl Med. 2016 Sep 21;8(357):357ra123
– reference: 16210613 - J Immunol. 2005 Oct 15;175(8):5095-103
– reference: 26476139 - Clin Immunol. 2017 Apr;177:50-59
– reference: 16641398 - N Engl J Med. 2006 Apr 27;354(17):1813-26
– reference: 16168521 - J Hepatol. 2005 Dec;43(6):1013-20
– reference: 24100387 - Immunol Cell Biol. 2013 Nov-Dec;91(10):615-24
– reference: 15914555 - Blood. 2005 Sep 1;106(5):1601-3
– reference: 11750709 - Lung Cancer. 2002 Jan;35(1):23-8
– reference: 16086548 - Chang Gung Med J. 2005 May;28(5):335-40
– reference: 20068163 - Cancer Res. 2010 Jan 15;70(2):440-6
– reference: 11698225 - Trends Immunol. 2001 Nov;22(11):633-40
– reference: 24616310 - J Clin Oncol. 2014 Apr 10;32(11):1157-63
– reference: 20188202 - Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14
– reference: 20655806 - Trends Immunol. 2010 Sep;31(9):339-45
– reference: 11719354 - Blood. 2001 Dec 1;98(12):3192-204
– reference: 24525278 - Biol Blood Marrow Transplant. 2014 May;20(5):696-704
– reference: 23906377 - J Allergy Clin Immunol. 2013 Sep;132(3):536-44
– reference: 24067492 - Leukemia. 2014 Apr;28(4):917-27
– reference: 24686272 - Mol Ther. 2014 Jul;22(7):1388-95
– reference: 22544698 - Blood. 2012 Jun 14;119(24):5758-68
– reference: 12918068 - Int J Cancer. 2003 Oct 10;106(6):905-12
– reference: 26692321 - J Hematol Oncol. 2015 Dec 21;8:130
– reference: 2201309 - Immunol Today. 1990 Jul;11(7):237-44
– reference: 20680271 - Cancer Immunol Immunother. 2010 Nov;59(11):1739-44
– reference: 27960589 - Expert Opin Biol Ther. 2017 Mar;17 (3):313-324
– reference: 10685650 - Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7
– reference: 24404423 - Oncoimmunology. 2013 Oct 1;2(10):e26527
– reference: 27059202 - Cytotherapy. 2016 May;18(5):653-63
– reference: 26174883 - Int J Cancer. 2016 Jan 1;138(1):187-94
– reference: 21841316 - J Clin Invest. 2011 Sep;121(9):3609-22
– reference: 16307421 - Klin Padiatr. 2005 Nov-Dec;217(6):345-50
– reference: 25006133 - Blood. 2014 Aug 14;124(7):1081-8
– reference: 24719405 - Blood. 2014 Jun 19;123(25):3855-63
– reference: 10649250 - Cancer. 2000 Feb 1;88(3):577-83
– reference: 27664326 - Biol Blood Marrow Transplant. 2016 Dec;22(12 ):2187-2193
– reference: 26787822 - Cancer Immunol Res. 2016 Mar;4(3):215-24
– reference: 9480992 - J Exp Med. 1998 Mar 2;187(5):813-8
– reference: 23286345 - J Hematol Oncol. 2013 Jan 04;6:1
– reference: 22279576 - PLoS One. 2012;7(1):e30264
– reference: 20849361 - Cytotherapy. 2011 Jan;13(1):98-107
– reference: 19551844 - Hepatology. 2009 Sep;50(3):799-807
– reference: 26190113 - Cell Rep. 2015 Jul 28;12(4):622-35
– reference: 22738379 - Transfusion. 2013 Feb;53(2):412-8; quiz 411
– reference: 26062124 - PLoS One. 2015 Jun 10;10 (6):e0123416
– reference: 3903508 - N Engl J Med. 1985 Dec 5;313(23):1485-92
– reference: 28280089 - Clin Cancer Res. 2017 Mar 9;:null
– reference: 28295190 - Br J Haematol. 2017 May;177(3):457-466
– reference: 28220124 - Front Immunol. 2017 Feb 06;8:87
– reference: 12900537 - Dig Surg. 2003;20(5):445-51
– reference: 19365083 - Blood. 2009 Jun 11;113(24):6094-101
– reference: 10381530 - Blood. 1999 Jul 1;94(1):333-9
– reference: 22032984 - Trends Pharmacol Sci. 2012 Jan;33(1):35-41
– reference: 23755121 - PLoS One. 2013 Jun 05;8(6):e64384
– reference: 19638467 - Clin Cancer Res. 2009 Aug 1;15(15):4857-66
– reference: 24366519 - Immunol Cell Biol. 2014 Mar;92(3):221-9
– reference: 27197065 - Cancer Immunol Res. 2016 Jul;4(7):574-81
– reference: 15457184 - Leukemia. 2004 Nov;18(11):1835-8
– reference: 22096557 - PLoS One. 2011;6(11):e27351
– reference: 22571679 - Stem Cells Dev. 2012 Nov 1;21(16):2926-38
– reference: 27090958 - Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-8
– reference: 17100888 - Immunol Rev. 2006 Dec;214:229-38
– reference: 12594840 - Eur J Immunol. 2003 Jan;33(1):119-24
– reference: 18292941 - Int J Oncol. 2008 Mar;32(3):633-41
– reference: 27783105 - Cancer Immunol Immunother. 2017 Jan;66(1):51-61
– reference: 18950462 - Br J Haematol. 2008 Dec;143(5):641-53
– reference: 9208838 - Immunity. 1997 Jun;6(6):655-61
– reference: 27050072 - Oncotarget. 2016 May 10;7(19):27764-77
– reference: 20567250 - Immunol Cell Biol. 2011 Feb;89(2):216-24
– reference: 22437938 - Nat Rev Immunol. 2012 Mar 22;12(4):253-68
– reference: 25728220 - Drug Discov Today. 2015 Jul;20(7):838-47
– reference: 26772158 - Biol Blood Marrow Transplant. 2016 Apr;22(4):705-9
– reference: 24752542 - Protein Cell. 2014 Jul;5(7):496-502
– reference: 9858524 - J Exp Med. 1998 Dec 21;188(12):2375-80
– reference: 21698239 - PLoS One. 2011;6(6):e20740
– reference: 26910920 - Oncotarget. 2016 Mar 29;7(13):16130-45
– reference: 23741009 - Blood. 2013 Aug 22;122(8):1341-9
– reference: 24496456 - Br J Cancer. 2014 Mar 4;110(5):1221-7
– reference: 11896281 - Science. 2002 Mar 15;295(5562):2097-100
– reference: 27530969 - Biol Blood Marrow Transplant. 2016 Nov;22(11):2065-2076
– reference: 3493433 - N Engl J Med. 1987 Apr 9;316(15):898-905
– reference: 24895051 - Eur J Immunol. 2014 Sep;44(9):2822-34
– reference: 20085940 - J Clin Oncol. 2010 Feb 20;28(6):955-9
– reference: 24896845 - PLoS One. 2014 Jun 04;9(6):e96705
– reference: 25887777 - Blood. 2015 Jun 25;125(26):4024-31
SSID ssj0000493335
Score 2.5292766
SecondaryResourceType review_article
Snippet Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 631
SubjectTerms adoptive natural killer cell therapy
allogeneic natural killer cells
autologous natural killer cells
hematopoietic stem cell transplantation
Immunology
natural killer cell biotech companies
natural killer cell combinatorial studies
Title The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
URI https://www.ncbi.nlm.nih.gov/pubmed/28620386
https://www.proquest.com/docview/1910793286
https://pubmed.ncbi.nlm.nih.gov/PMC5450018
https://doaj.org/article/64f543aec174413db67dc06b1cfe3add
Volume 8
WOSCitedRecordID wos000402338000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9QwFA66KHgRfzurLhG8eCjTTtK08TYOO7iowyIKcwv58YKVbkemMwt72b_dl6Q7zIjoxUsOSUvTfC_J98jL9wh5Y3Nvbe19xjUYdFCgzGopeCa8A2m0y42P6vqfqsWiXi7l-V6qrxATluSB08CNBfclZxosUmdccJ0RlbO5MIX1wHByhtUXWc-eM_Uj8V7GWJnOJdELk2PfXFxsQyhXkCwUrDjYh6Jc_5845u-hknt7z_wBuT-QRjpNnX1IbkH3iNxNaSSvHpNrxJp-aXqgK0-nLVbiAtZYutBRVIN-jPf96AzatqfTnmp63upNYKsUCzoLwK_pWbgpMtzHunpHkU9iZ-jZLmsqvtc5Oo8aJHQv1qh_Qr7NT7_OPmRDXoXMlpN6k2lhva5KREEWFhzPTRHOR8Eg-wAhfI6tNpeA7A-dtwoZrUSvTtjCecdrcOwpOepWHTwnlIOwRiMFtMZxYSvNpTc5TBiTmiNAIzK-GWVlB9HxkPuiVeh8BFxUxEUFXFTEZUTe7t74mQQ3_vLs-wDc7rkglR0r0IDUYEDqXwY0Iq9vYFc4tcJ5ie5gte0V_nSQD5zUYkSeJTPYfQorJzkLLdWBgRz05bCla75H-W7krCEV4vH_6PwLci8MRwpneEmONustvCJ37OWm6dcn5Ha1rE_izMDy8_XpLzc0GSU
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Rise+of+Allogeneic+Natural+Killer+Cells+As+a+Platform+for+Cancer+Immunotherapy%3A+Recent+Innovations+and+Future+Developments&rft.jtitle=Frontiers+in+immunology&rft.au=Veluchamy%2C+John+P.&rft.au=Kok%2C+Nina&rft.au=van+der+Vliet%2C+Hans+J.&rft.au=Verheul%2C+Henk+M.+W.&rft.date=2017-05-31&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=8&rft_id=info:doi/10.3389%2Ffimmu.2017.00631&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2017_00631
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon